Overview

A Pharmacodynamic Study of Measured Glomerular Filtration Rate in Patients With Chronic Kidney Disease and Type 2 Diabetes

Status:
Terminated
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
This is a 24-week multi-center, double-blind, randomized, exploratory study of bardoxolone methyl treatment in 18 patients with Stage 3 CKD (eGFR greater than or equal to 30.0 to less than 60.0 ml/min/1.73m2) and diabetes to ensure at least 15 patients complete the study for evaluation of the primary endpoints.
Phase:
Phase 1
Details
Lead Sponsor:
Reata Pharmaceuticals, Inc.